Alfa Wassermann SpA-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Alfa Wassermann SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011845
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alfa Wassermann SpA (Alfa Wassermann), a subsidiary of AlfaSigma SpA is a pharmaceutical company which produces and distributes drugs for human health. The company provides new discoveries in medicine, biology and genomics. Alfa Wassermann finds solutions for paradox treatment. The company offers self meditation products for sore throat, headaches, and muscle and joint pain treatments. It also provides antibiotics used for treatment of diseases such as vascular diseases, deep venous thrombosis and gastrointestinal tract diseases. Alfa Wassermann operates through its offices located in the US, the Netherlands, Mexico, France, Spain, Portugal, China, Poland, Romania, Tunisia and Slovakia. Alfa Wassermann is headquartered in Bologna, Italy.

Alfa Wassermann SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alfa Wassermann SpA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Alfa Wassermann SpA, Medical Devices Deals, 2011 to YTD 2017 9
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 12
Partnerships 14
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 14
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 16
European Institute of Oncology Enters Into Co-Development Agreement With Sigma Tau Industrie 17
Theravance Enters Into Co-Development Agreement With Alfa Wassermann For Velusetrag 18
a V.I. Pharma Enters into Distribution Agreement with Sigma-Tau for Eurartesim 19
Ezose Sciences Enters Into R&D Agreement With Sigma-Tau Industrie Farmaceutiche 20
Licensing Agreements 21
CVie Therapeutics Enters into Licensing Agreement with Sigma-Tau Industrie 21
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 22
Sigma-Tau Pharma Enters into Licensing Agreement with Crosscare for Colief 23
Lee’s Pharma HK Enters into Licensing Agreement with Sigma-Tau Industrie Farmaceutiche Riunite 24
CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau 25
CVie Therapeutics to Enter into Licensing Agreement with RostaQuo 27
Soligenix Expands Licensing Agreement With Sigma-Tau Pharma For orBec 29
Equity Offering 31
RegeneRx BioPharma Completes Registered Direct Offering Of US$1.45 Million 31
Asset Transactions 33
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 33
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 34
Acquisition 36
Sigma-Tau May Sell Sigma-Tau Pharma 36
Alfa Wassermann Acquires Promefarm 37
Alfa Wassermann SpA – Key Competitors 38
Alfa Wassermann SpA – Key Employees 39
Alfa Wassermann SpA – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Key Facts 2
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alfa Wassermann SpA, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alfa Wassermann SpA, Deals By Therapy Area, 2011 to YTD 2017 8
Alfa Wassermann SpA, Medical Devices Deals, 2011 to YTD 2017 9
Alfa Wassermann SpA, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 12
Salix Pharma Enters Into Licensing Agreement With Alfa Wassermann For Rifaximin 14
Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 16
European Institute of Oncology Enters Into Co-Development Agreement With Sigma Tau Industrie 17
Theravance Enters Into Co-Development Agreement With Alfa Wassermann For Velusetrag 18
a V.I. Pharma Enters into Distribution Agreement with Sigma-Tau for Eurartesim 19
Ezose Sciences Enters Into R&D Agreement With Sigma-Tau Industrie Farmaceutiche 20
CVie Therapeutics Enters into Licensing Agreement with Sigma-Tau Industrie 21
Pierre Fabre Labs Enters into Licensing Agreement with Sigma-Tau 22
Sigma-Tau Pharma Enters into Licensing Agreement with Crosscare for Colief 23
Lee’s Pharma HK Enters into Licensing Agreement with Sigma-Tau Industrie Farmaceutiche Riunite 24
CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau 25
CVie Therapeutics to Enter into Licensing Agreement with RostaQuo 27
Soligenix Expands Licensing Agreement With Sigma-Tau Pharma For orBec 29
RegeneRx BioPharma Completes Registered Direct Offering Of US$1.45 Million 31
Alfa Wassermann Acquires Italian Operations from Sigma-Tau 33
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 34
Sigma-Tau May Sell Sigma-Tau Pharma 36
Alfa Wassermann Acquires Promefarm 37
Alfa Wassermann SpA, Key Competitors 38
Alfa Wassermann SpA, Key Employees 39
Alfa Wassermann SpA, Other Locations 40
Alfa Wassermann SpA, Subsidiaries 40

★海外企業調査レポート[Alfa Wassermann SpA-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Immupharma Plc (IMM):企業の財務・戦略的SWOT分析
    Immupharma Plc (IMM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Reliance Capital Ltd:企業のM&A・事業提携・投資動向
    Reliance Capital Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Reliance Capital Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Brewers Fayre:企業の戦略・SWOT・財務分析
    Brewers Fayre - Strategy, SWOT and Corporate Finance Report Summary Brewers Fayre - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Novacyt SA (ALNOV):企業の財務・戦略的SWOT分析
    Summary Novacyt SA (Novacyt) is a medical device company that develops and markets medical cytology solutions. The company offers oncology and infectious disease diagnostic products. It also sells diagnostic reagents used in LBC, oncology, microbiology, haematology and serology testing. Novacyt deve …
  • Provectus Biopharmaceuticals Inc (PVCT):医療機器:M&Aディール及び事業提携情報
    Summary Provectus Biopharmaceuticals Inc (Provectus) is a developer of pharmaceuticals for oncology and dermatology indications. The company provides pipeline products such as PV-10 for locally advanced cutaneous melanoma, PV-10 for metastatic liver cancer and PV-10 for neuroendocrine tumors [NET], …
  • Informa plc:企業の戦略・SWOT・財務分析
    Informa plc - Strategy, SWOT and Corporate Finance Report Summary Informa plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • AiCuris GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報
    Summary AiCuris GmbH & Co KG (AiCuris) a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company’s pipeline products include antiviral and antibacterial agents f …
  • Assertio Therapeutics Inc (ASRT):企業の財務・戦略的SWOT分析
    Assertio Therapeutics Inc (ASRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Synthetic Biologics Inc (SYN):企業の財務・戦略的SWOT分析
    Summary Synthetic Biologics Inc (Synthetic Biologics), formerly Adeona Pharmaceuticals Inc is a clinical company that develops novel therapeutics to treat gut microbiome. The company’s pipeline products include SYN-004 and SYN-010. Its SYN-010 is a proprietary, modified-release formulation which is …
  • Laborie Medical Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Laborie Medical Technologies Inc (Laborie), a subsidiary of Patricia Industries AB, develops and manufactures medical diagnostics and devices. The company offers uroflowmetry, urodynamics, pelvic floor rehabilitation and anorectal manometry products and related consumables. It also provides …
  • Fingrid Oyj:企業の発電所・SWOT分析2018
    Fingrid Oyj - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • Clearside BioMedical Inc (CLSD):医療機器:M&Aディール及び事業提携情報
    Summary Clearside BioMedical Inc (Clearside) is a clinical biopharmaceutical company that develops treatments for vision impairment associated with uveitic macular edema. The company’s pipeline products comprise Uveitis, macular edema associated with non- infectious uveitis; RVO - Retinal Vein Occlu …
  • Leigh Creek Energy Ltd (LCK):企業の財務・戦略的SWOT分析
    Leigh Creek Energy Ltd (LCK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Alexion Pharmaceuticals Inc (ALXN):企業の財務・戦略的SWOT分析
    Alexion Pharmaceuticals Inc (ALXN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Daito Trust Construction Co., Ltd.:企業の戦略・SWOT・財務情報
    Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daito Trust Construction Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Natco Pharma Ltd (NATCOPHARM):企業の財務・戦略的SWOT分析
    Natco Pharma Ltd (NATCOPHARM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Gardner Denver Holdings, Inc. (GDI):企業の財務・戦略的SWOT分析
    Gardner Denver Holdings, Inc. (GDI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Qatar Holding LLC:企業のM&A・事業提携・投資動向
    Qatar Holding LLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Qatar Holding LLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Cryostar SAS:企業の戦略的SWOT分析
    Cryostar SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Metagenics Inc:企業の戦略的SWOT分析
    Metagenics Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆